Forthcoming Submission: trastuzumab emtansine (Kadcyla)
Indication: As a single agent for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: • received prior therapy for locally advanced or metastatic disease, or • developed disease recurrence during or within six months of completing adjuvant therapy.
|Drug Name:||trastuzumab emtansine (Kadcyla)|
|Submission type:||Full submission|
|Patient Interest Group
|SMC Meeting Date:||2/09/2014|